February 14, 2012
Allena Pharmaceuticals Appoints Gino Santini to Board of Directors » Press Release | Company News
February 1, 2012
NinePoint Medical Announces Formation of Clinical and Technology Advisory Boards » Press Release | Company News
Launching Transforming Companies Together
"Over the last 12 months, I have seen a dramatic increase in the active collaboration between leaders of the Third Rock portfolio companies. I am able to tap into my peers for perspectives on everything from compensation to recruitment, and they've tapped into Agios for insights into partnering and financing. By better connecting Third Rock's portfolio company leadership teams to each other, we are learning from one another and helping each other navigate the company building process."
David Schenkein, M.D. Chief Executive Officer of
Agios Pharmaceuticals
Third Rock Ventures was founded in 2007 with the mission to launch transforming companies. We set out to build a different firm – a firm that was squarely focused on launching exceptional life science companies with passionate entrepreneurs, working in areas of disruptive science to make a difference in the lives of patients. In just three short years, and during a period of time when early stage investing has been in flux, we have successfully raised more than $800 million to accomplish this mission. We truly believe that nothing is impossible.
Our innovative and hands-on approach to launching, building and operating promising life science companies is unique, and we have assembled a team with deep expertise and a proven track record of building some of the most respected and successful life sciences companies. With decades of complementary, cross-functional operational and leadership experience, we have the breadth and depth of expertise to actively engage and collaborate with our portfolio companies, and where needed, initially fill key leadership roles, to provide hands-on strategy and experience to successfully launch companies with the best vision, science, operations, people and culture.
We take investments in our companies and our people seriously, as we strive to be the best business partners in the world. By working closely with the scientific and business communities, we seek to identify the most promising opportunities for the future of medicine and then build the team and company structure to make this visionary science a business reality. We also assess early stage opportunities, in which we can partner in unique ways with larger pharmaceutical and biotechnology companies to found companies together that are based on disruptive science and technology to address unmet needs.
Our approach is bold, our thinking is outside-of-the-box and we apply the same innovative spirit to our deal-making as we do to our companies’ science. Together, this approach is designed to achieve our ultimate goal - launching transforming companies that make a difference for patients through breakthroughs in medicine.
